arrow_back_ios Back View more articles
Thermo Fisher Scientific

Swindon to become Pfizer’s UK centre in battle against Covid

A Swindon company will become the first in the UK to produce the Pfizer Covid-19 vaccine.

The deal is set to bring £70 million of investment – mainly around the expansion of production lines and the installation of ultra-cold storage – and 200 jobs to Swindon.

The news was confirmed by the Prime Minister at the Conservative Party conference yesterday (Wednesday).

The vaccine will be produced at the Thermo Fisher Scientific site on Kingfisher Drive – marking the first time that the vaccine will be made or bottled in the UK.

Production is expected to begin in early 2022, once Pfizer has received regulatory approval.

The company confirmed: “The investment emphasises the demand for steriles globally and helps us support fast-tracked development of vaccines and treatments to patients – whether it be for Covid-19 or other serious diseases.

“One of the ways this is being accomplished is through the addition of a new business model. As part of the site expansion, Swindon will add a commercial manufacturing model, allowing us to offer whole line, end-to-end capacity for several customers, giving the site greater stability and growth potential.

“This change will also provide the capacity customers need right now to help in the pandemic fight.

“Swindon’s expansion will transform the 30,000-square-foot site into a new full-scale commercial manufacturing facility that can provide short- and long-term capacity for the pandemic and other commercial manufacturing projects.

“The expansion includes two new sterile fill/finish lines for liquid and lyophilised filling, as well as extensive cold chain storage for vaccines requiring ultra-low temperatures.”